LabCorp Begins Offering Exact Sciences’ PreGen-Plus Colorectal Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
Exact Sciences hopes consultation with FDA on clinical utility trials for the firm's PreGen-Plus colorectal cancer screening assay will help fulfill potential regulatory requirements in the future
You may also be interested in...
FDA May Require Premarket Clearance For Exact Sciences’ PreGen-Plus
LabCorp will continue to market Exact Sciences' PreGen-Plus colorectal cancer screening assay pending further word from FDA, which has indicated that the diagnostic may require regulation as a medical device, Exact Sciences says
FDA May Require Premarket Clearance For Exact Sciences’ PreGen-Plus
LabCorp will continue to market Exact Sciences' PreGen-Plus colorectal cancer screening assay pending further word from FDA, which has indicated that the diagnostic may require regulation as a medical device, Exact Sciences says
Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
Abbott Labs is urging CDRH to clarify that its April 1draft guidance on multiplex tests for heritable markers, mutations and expression patterns applies only to device submissions